

WIPO/GC/INN/GE/11/INF/1 PROV. ORIGINAL: ENGLISH DATE: OCTOBER 19, 2011

Launch of WIPO Re:Search: Sharing Innovation in the Fight Against Neglected Tropical Diseases

Geneva, October 26, 2011

PROVISIONAL PROGRAM

prepared by the Secretariat

Wednesday October 26, 2011

14h00 – 14h10 Opening Remarks by:

Mr. Francis Gurry, Director General, World Intellectual Property Organization (WIPO), Geneva

14h10 – 15h30 Roundtable Discussion:

The Roundtable will examine the questions regarding the challenges of stimulating innovation in the field of Neglected Tropical Diseases (NTDs), malaria and tuberculosis, and how WIPO Re:Search will help find solutions to these challenges.

Moderator: Mr. Francis Gurry, WIPO

Panelists: His Excellency Mr. Matern Yakobo Christian

Lumbanga, Ambassador, Permanent Representative of the United Republic of Tanzania to the United Nations Office at

Geneva

His Excellency Mr. Tom Mboya Okeyo, Ambassador, Permanent Representative of the Republic of Kenya to the United Nations Office at Geneva

Dr. Margaret Chan, Director General, World Health Organization (WHO)

Mr. David Brennan, Chief Executive Officer, AstraZeneca PLC

Dr. Jorge Bermudez, Vice President, Production and Innovation in Health, Fundação Oswaldo Cruz (Fiocruz)

Dr. Muhammad Ali Dhansay, Acting President, Medical Research Council, South Africa

Ms. Alisa Harbin, Head of Group Intellectual Property, Novartis

Dr. David Jefferys, Senior Vice President Global Regulatory, Government Relations, Public Affairs and European Product Safety, Eisai Europe Ltd.

WIPO/GC/INN/GE/11/INF/1 PROV. page 3

Mr. Donald Joseph, Chief Operating Officer, BIO Ventures for Global Health (BVGH)

Mr. Duncan Learmouth, Senior Vice President, Developing Countries & Market Access, GlaxoSmithKline

Ms. Geralyn Ritter, Vice President, Global Public Policy and Corporate Responsibility, Merck & Co., Inc.

Dr. Robert Sebbag, Vice President Access to Medicines, Sanofi

Mr. Roy Waldron, Senior Vice President, Associate General Counsel & Chief Intellectual Property Counsel, Pfizer Inc.

[End of document]